A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Read time: 1 mins
Last updated:23rd Apr 2014
This is an open-label, single-arm, multicentre, global, Phase II, study designed to evaluate the efficacy and safety of AZD6094 in patients with PRCC who are treatment naïve or previously treated.
|Study start date||2014-04-23|